---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009999"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:45:40.331552+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals

## Summary
- FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.
- Restructuring substantially complete; $7.7M in charges incurred in 2022.
- AbbVie terminates CX-2029 collaboration; CytomX regains full rights to CD71 program.
- CX-904 Phase 1 dose escalation progressing; IND filings for CX-801 & CX-2051 expected 2H 2023.
- New collaborations: Moderna ($35M upfront) and Regeneron ($30M upfront) with up to $1.2B and $2B milestones.

## SEC filing metadata
- accession: 0000950170-23-009999
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/0000950170-23-009999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/ctmx-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009999
- JSON: https://secwatch.observer/filing/0000950170-23-009999.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009999.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 27, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/0000950170-23-009999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.